APx Acquisition Corp. I (APXI)
| Previous close | 11.67 |
| Open | 11.63 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 11.63 - 11.64 |
| 52-week range | 10.92 - 11.70 |
| Volume | |
| Avg. volume | 7,301 |
| Market cap | 115.354M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 33.26 |
| EPS (TTM) | 0.35 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireAPX Acquisition Corp. I Reports 10-K Delinquency Notice
APX Acquisition Corp. I (NASDAQ: APXI) ("Company"), a publicly traded special purpose acquisition company, today announced that it received a deficiency letter (the "Letter") on May 30, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq"). The Letter notified the Company that since the Company had not yet filed its Annual Report on Form 10-K for the year ended December 31, 2023 (the "Form 10-K") and its Quarterly Report on Form 10-Q for the quarter ended March 31
PR NewswireAPx Acquisition Corp. I, OmnigenicsAI Corp and MultiplAI Health Ltd enter into Business Combination Agreement to create a global AI-driven genomics platform
APx Acquisition Corp. I (NASDAQ: APXI) ("APx"), a publicly traded special purpose acquisition company, OmnigenicsAI Corp ("OmnigenicsAI"), a precision medicine company incubated by Bioceres Group PLC, and MultiplAI Health Ltd ("MultiplAI"), a UK-based AI-enabled preventive medicine company, have entered into a definitive Business Combination Agreement ("BCA") that, upon closing, would result in OmnigenicsAI becoming a publicly listed company. The transaction is expected to close mid-year, subjec
PR NewswireAPX Acquisition Corp. I receives Nasdaq notice on late filing of its Form 10-Q
APX Acquisition Corp. I (NASDAQ: APXI) ("Company"), a publicly traded special purpose acquisition company, today announced that it received a deficiency letter (the "Letter") on December 21, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq"). The Letter notified the Company that since the Company had not yet filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the "Form 10-Q"), the Company does not comply with Nasdaq's Listing Rule
